Figure 1.
Figure 2.
Figure 3.
Figure 4.
Changes in the DBP of patients with hypertension in garlic-treated cases and controls or placebo
| Author name and year | Mean ± SD DBP pretreated garlic group (mmHg) | Mean ± SD DBP post-treated garlic group (mmHg) | Mean ± SD DBP pretreated placebo group (mmHg) | Mean ± SD DBP post-treated placebo group (mmHg) |
|---|---|---|---|---|
| Kandziora [32] | 100 ± 4 | 85 ± 4 | 100 ± 3 | 91 ± 6 |
| Auer et al. [22] | 101 ± 14.7 | 89 ± 4.6 | 97 ± 9.6 | 94 ± 9.6 |
| Vorberg and Schneider [28] | 91 ± 4 | 87 ± 4 | 87.5 ± 6 | 90 ± 4 |
| De Santos and Gruenwald [29] | 89 ± 11 | 80 ± 4.6 | 89 ± 11 | 90 ± 8.3 |
| Sobenin et al. [26] | 88.8 ± 4.3 | 83.8 ± 3.4 | 87.9 ± 4.8 | 85.9 ± 4.4 |
| Sobenin et al. [27] | 95.7 ± 3.8 | 92.9 ± 4.4 | 94.4 ± 6.1 | 93 ± 6.1 |
| Ried et al. [25] | 87.3 ± 7.8 | 91.9 ± 8.3 | 88.6 ± 8 | 84 ± 8.3 |
| Ried et al. [24] | 75.7 ± 12.4 | 68.6 ± 11.6 | 76 ± 12.2 | 70.2 ± 12 |
| Nakasone et al. [23] | 90.9 ± 6.9 | 87 ± 7.1 | 91.6 ± 5.8 | 90.7 ± 6.5 |
| Ried et al. [9] | 89.9 ± 11.7 | 86.1 ± 11.3 | 87.8 ± 9.1 | 86 ± 9 |
| Ried et al. [30] | 93 ± 10.9 | 83.1 ± 10.4 | 90 ± 12.3 | 85.5 ± 13 |
| Serrano et al. [31] | 85 ± 10 | 83 ± 9 | 85 ± 7 | 83 ± 10 |
Characteristics and changes in the SBP of patients with hypertension in garlic-treated cases and controls or placebo
| Author name and year (reference) | Population | Number of subjects in garlic-treated group/control or placebo group | Mean BMI kg/m2 (treated/control group) | Medication at baseline | Manufacturer, dose (mg/d)/duration of treatment (weeks) | Mean ± SD SBP pretreated garlic group (mmHg) | Mean ± SD SBP post-treated garlic group (mmHg) | Mean ± SD SBP pretreated placebo group (mmHg) | Mean ± SD SBP post-treated placebo group (mmHg) |
|---|---|---|---|---|---|---|---|---|---|
| Kandziora [32] | Poland | 20/20 | NA | Triamterene/hydrochlorothiazide | Kwai, 600/12 | 178 ± 8 | 162 ± 9 | 178 ± 8 | 173 ± 6 |
| Auer et al. [22] | Germany | 24/23 | NA | NA | Kwai, 600/12 | 171 ± 24.5 | 152 ± 24.5 | 161 ± 14.4 | 152 ± 19.2 |
| Vorberg and Schneider [28] | Germany | 20/20 | NA | NA | Kwai, 900/16 | 144 ± 10.6 | 138 ± 4 | 143.5 ± 10 | 146 ± 6.5 |
| De Santos and ruenwald [29] | Germany | 25/27 | NA | NA | Kwai, 900/24 | 143 ± 21 | 120 ± 13.1 | 144 ± 17 | 145 ± 11.7 |
| Sobenin et al. [26] | Russia | 23/19 | 26.6/27.0 | NA | Allicor, 600/12 | 143.4 ± 7.2 | 136.8 ± 5.8 | 140.3 ± 78 | 139.4 ± 6.5 |
| Sobenin et al. [27] | Russia | 64/20 | 25.4/26.0 | NA | Allicor, 2,400/8 | 154 ± 12.3 | 147 ± 12.8 | 149.8 ± 12.6 | 149.9 ± 11.7 |
| Ried et al. [25] | Australia | 8/12 | 31.0/29.1 | ACE inhibitors, A2 receptor antagonists, β-receptor blockers, Ca-antagonists, and diuretics | Kyolic High Potency, 960/12 | 151.2 ± 7.7 | 136 ± 8 | 152.8 ± 9.3 | 145.4 ± 3.5 |
| Ried et al. [24] | Australia | 39/19 | 29.1/29.9 | ACE inhibitors, A2 receptor ant-agonists, β-receptor blockers, Ca-antagonists, diuretics | Kyolic High Potency, 480/12 | 149.3 ± 13 | 130 ± 12.8 | 148.6 ± 13.1 | 135.9 ± 12.8 |
| Nakasone et al. [23] | Japan | 23/24 | 25.0/23.0 | None | Dentou ninniku ranwo, 188/12 | 141.8 ± 5.6 | 137 ± 7.8 | 141.8 ± 5.6 | 140.4 ± 7.6 |
| Ried et al. [9] | Australia | 50/38 | 27.3/28.3 | ACE inhibitors, A2 receptor antagonists, β-receptor blockers, Ca-antagonists, and diuretics | Kyolic Reserve, 1,200/12 | 148.7 ± 15.3 | 141.7 ± 15.3 | 142 ± 9.4 | 140.3 ± 18.2 |
| Ried et al. [30] | Australia | 23/26 | 28.6/29.7 | ACE inhibitors, A2 receptor antagonists, β-receptor blockers, Ca-antagonists, and diuretics | Kyolic Reserve, 1,200/12 | 153.3 ± 16.4 | 139 ± 15.1 | 144.3 ± 14.2 | 140 ± 16.3 |
| Serrano et al. [31] | Spain | 39/38 | NA | Thiazide, beta blockers, angiotensin II receptor blocker, and calcium channel blockers | Pharmactive Biotech Spain, 300/12 | 146 ± 21 | 143 ± 18 | 144 ± 13 | 138 ± 14 |